AL 16049

Drug Profile

AL 16049

Latest Information Update: 19 Dec 2006

Price : $50

At a glance

  • Originator Alcon
  • Class
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 03 Dec 2003 No development reported - Preclinical for Glaucoma in USA (unspecified route)
  • 20 Sep 2001 Preclinical development for Glaucoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top